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ORIGINAL STUDYSexually Transmitted Infection Testing of HIV-Positive
Medicare and Medicaid Enrollees Falls Short
of Guidelines
Raphael J. Landovitz, MD, MSc,* Jennifer L. Gildner, MS,† and Arleen A. Leibowitz, PhD†Background:Men who have sex with men with HIV have high sexually
transmitted infection (STI) incidence. Thus, the Centers for Disease Control
and Prevention (CDC) recommends at least yearly STI screening of HIV-
infected individuals.
Methods:We calculated testing rates for syphilis, chlamydia, and gonorrhea
among HIV-positive Californians with Medicare or Medicaid insurance in
2010. Logistic regressions estimated how testing for each bacterial STI relates
to demographic and provider factors.
Results: Fewer than two-thirds of HIV-positive Medicare and fewer than
three-quarters of Medicaid enrollees received a syphilis test in 2010.
Screenings for chlamydia or gonorrhea were less frequent: approximately
30% of Medicare enrollees were tested for chlamydia or gonorrhea in
2010, but higher proportions of Medicaid enrollees were tested (45%–
46%). Only 34% of HIV-positive Medicare enrollees who were tested for
syphilis were also screened for chlamydia or gonorrhea on the same day.
Nearly half of Medicaid enrollees were tested for all 3 STIs on the same
day. Patients whose providers had more HIV experience had higher STI
testing rates.
Conclusions: Testing rates for chlamydia and gonorrhea infection are
low, despite the increase in these infections among people living with
HIVand their close association with HIV transmission. Interventions to in-
crease STI testing include the following: prompts in the medical record to
routinely conduct syphilis testing on blood drawn for viral load monitoring,
opt-out consent for STI testing, and provider education about the clinicalFrom the *Division of Infectious Diseases, UCLA David Geffen School of
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8 Sexuallimportance of STIs among HIV-positive patients. Last, it is crucial to
change financial incentives that discourage nucleic acid amplification
testing for rectal chlamydia and gonorrhea infections.
The Centers for Disease Control and Prevention1 estimates that1.9 million new cases of bacterial sexually transmitted infec-
tions (STIs; primary and secondary [P&S] syphilis, chlamydia,
gonorrhea) were diagnosed in the United States in 2015. After
years of decline, rates of STI have been growing. The national rate
of reported P&S syphilis was 4 times greater in 2015 than it had
been in 2000.1 Reported new chlamydia diagnoses grew by
90% between 2000 and 2015.1 Rates of gonorrhea infection
per 100,000 population reached a historic low in 2009 but in-
creased 26% by 2015.1
Bacterial STIs are prevalent among people living with HIV
(PLWH), reflecting high rates among men who have sex with men
(MSM), who account for 78% of HIV transmissions nationally.2
Men who have sex with men now account for 60% of all P&S
syphilis cases and 82% of the cases among men. Between 2007
and 2013, the number of new cases of syphilis among MSM grew
from approximately 5000 per year to 8200 per year, an increase of
64%.3 Black MSM had more than twice the rates of incident P&S
syphilis as compared with all MSM. Furthermore, P&S rates are
growing particularly among young (13–24 years), black MSM
living in the largest metropolitan areas, who reported twice the
number of syphilis diagnoses in 2008 as they had in 2004.4
Among MSM, the HIV-infected have the highest preva-
lence and experienced the greatest increase in syphilis diagnosis.5
Among MSM visiting Sexually Transmitted Disease Surveillance
Network clinics, prevalence of P&S syphilis was 10.3% among
HIV-positive men and 2.6% among HIV-negative MSM.1 HIV-
positive MSM accounted for 82% of the syphilis cases among
men in 2015.1 The high rates of syphilis among HIV-positive
MSM are a particular health concern6 because syphilis infection
increases HIV viral load and decreases CD4 in HIV-infected
persons, thereby increasing the chance that PLWH transmit
the virus.7–10
To detect asymptomatic STIs, the Centers for Disease Con-
trol and Prevention (CDC) recommends at least annual STI testing
for MSM rather than symptom-driven testing.11 Men who have
sex with men are more likely than other men to be tested for STIs
at least once annually (26.2% vs 15.6%), yet STI testing is far from
universal, even among HIV-positive MSM, who have the highest
rates of STIs.1 Among people in treatment of HIV monitored
in the Medical Monitoring Project, only 43% of sexually active
PLWH received a test for gonorrhea, 43% for chlamydia, and
65% for syphilis in calendar 2013.2,12,13 Screening rates were
even lower in a sample of commercially insured HIV-positive
patients aged 18 to 64 years: 22.2% were tested for chlamydia,
21.9% for gonorrhea, and 51.1% for syphilis.14 Hoover et al.15
found relatively high annual rates of screening for syphilis
(66%–76%) in large HIV clinics in 2004 to 2006, perhapsy Transmitted Diseases • Volume 45, Number 1, January 2018
HIV-Positive Medicare and Medicaid Enrolleesattributable to the fact that 7 of the 8 sites studied were RyanWhite
clinics, which are required to screen for syphilis. These clinics had
lower rates of testing for chlamydia and gonorrhea (2.3%–18%),
and most of these tests did not include rectal testing.
Given the high rates of syphilis, gonorrhea, and chlamydia
among PLWH, it is important to knowwhether people in treatment
of HIV meet minimum CDC guidelines for annual screening for
STIs. We examine the factors that relate to the odds of PLWH
being tested for syphilis, chlamydia, and gonorrhea in 2010. This
article extends the research on STIs among PLWHby examining a
large sample of PLWHwith Medicare or Medicaid insurance who
received medical care in a variety of settings.
MATERIALS AND METHODS
Data
Medicare and Medicaid claims data for HIV-positive
Californians were acquired through a confidential data use agree-
ment with the Centers for Medicare and Medicaid Services
(CMS). We distinguished Medicare beneficiaries enrolled solely
in Medicare from those enrolled dually in both Medicare (the
primary payer) and Medicaid (hereafter, Duals). Beneficiaries
enrolled solely in Medicaid (Medicaid-only) were analyzed
separately. We applied a case identification algorithm to create
an analysis file of adult beneficiaries with verifiable HIV.16 The
sample includes full-year fee-for-service enrollees, because
managed care data lack diagnosis fields needed to confirm
HIV status. Nearly half of the 6246 Medi-Cal enrollees who
met the previously mentioned criteria (3104) were not included
in the analysis sample because they visited a federally qualified
or a rural health center and therefore lacked claims data to docu-
ment procedures such as STI testing. There were 3142 individuals
in the Medi-Cal analysis sample. None of the 11,465 Medicare
enrollees were dropped for this reason.
Data acquisition was reviewed and approved by the CMS
Privacy Board. Research was also approved by the UCLA Institu-
tional Review Board.
Outcome Variables
This article examines testing for 3 bacterial STIs (chlamydia,
gonorrhea, and syphilis). Outpatient claim procedure codes shown
in Appendix A were used to identify tests for each of the 3 STIs
at least once during the year.
Predictor Variables
Enrollment data from CMS provided information on partic-
ipant sex, age (<40, 40-54, and ≥55 years), and race and ethnicity
(non-Hispanic white, African American, Hispanic, other). Reason
for Medicare or Medicaid coverage was coded as “disability” or
other (eg, aged). A provider's HIV patient case load predicts
quality of care better than provider specialty17; thus, we measure
an individual's access to an HIV specialist by whether he/she had
an evaluation andmanagement visit with any provider who treated
50 or more Medicare or Medicaid HIV patients in California
in 2010.18
Statistical Analysis
Screening rates for each of the STIs were calculated by pa-
tient characteristics separately for Medicare and Medicaid-only
enrollees. We also examined how frequently the STI screenings
were performed at the same visit. We estimated logistic regressions
to examine how testing for each of the bacterial STIs relates to
demographic factors.Sexually Transmitted Diseases • Volume 45, Number 1, January 20RESULTS
Sample Characteristics
There were 11,465 PLWH covered by Medicare (10,238 men
and 1227 women) in California in 2010 (Table 1). In addition, there
were 3142 PLWH (2298 men and 844 women) meeting the sample
inclusion criteria who were covered only by Medicaid. Consistent
with the demographics of the 115,700 PLWH in California in
2010,19 most of both samples were male (89% of the Medicare
sample and 73% of the Medicaid sample). Racial composition
differed between the 2 groups. The Medicare sample was 58%
white and 19% African American. The Medicaid-only sample was
37% white and 34% African American. Hispanics constituted 19%
of each insurance group (Table 1). Younger PLWH (≤40 years)
account for larger shares of the Medicaid (18%) than the Medicare
samples (7%).
STI Testing Rates
Rates of syphilis testing for Medicaid enrollees were higher
than for Medicare enrollees in 2010 (74% vs 65%). Screenings for
chlamydia or gonorrheawere much less frequent than for syphilis.
Approximately 30% of Medicare enrollees were tested for chla-
mydia or gonorrhea in 2010, but higher proportions of Medicaid
enrollees were tested (45%–46%; Table 1). Women were some-
what less likely than men to receive a syphilis test (51% of female
Medicare enrollees and 68% of female Medicaid enrollees were
tested for syphilis in 2010; P < 0.001 in both cases).
There was considerable overlap in testing for chlamydia or
gonorrhea. In 97% of the cases, a test for chlamydiawas accompa-
nied by a test for gonorrhea on the same day. However, only 34%
of Medicare PLWH enrollees tested for syphilis were screened for
chlamydia or gonorrhea on the same day (a total of 38% within
30 days of a syphilis test.) However, nearly half of Medicaid
enrollees who were tested for syphilis also received tests for
gonorrhea and chlamydia on the same day (53% within a month
of the syphilis test).
Multivariate Predictors of STI Testing
Table 2 presents logistic regression estimates of the effect
of predictor variables on the odds of being tested for each of the
3 bacterial STIs. Women were less likely to be tested for syphilis
than men in both Medicare (adjusted odds ratio [aOR], 0.52;
95% confidence interval [CI], 0.46–0.59) and Medicaid (aOR,
0.66; 95% CI, 0.55–0.79) samples. African American Medicare
enrollees had significantly greater odds of being tested for chlamydia
(aOR, 1.22; 95% CI, 1.09–1.36) and gonorrhea (aOR, 1.19; 95% CI,
1.06–1.33) compared with whites. Hispanic enrollees were more
likely than whites to be tested for each of the bacterial STIs, with
the exception of Medicaid testing for syphilis. Testing for chlamydia
and gonorrhea was more likely for those younger than 40 years than
for those 40 years or older. Medicare enrollees older than 55 years
were also less likely to be tested for syphilis than those younger than
40 years. Medicare patients with access to providers with greater
HIV caseloadswere more likely to be tested for all 3 bacterial STIs
than those without access to a high-volume HIV provider. Medic-
aid patients with access to large-volumeHIV providers had greater
odds of getting tested for syphilis compared with those with only
low-volume providers, but this was not the case for chlamydia
or gonorrhea.
DISCUSSION
Responding to what has been called a “hidden epidemic”20
and the fact that manywho are infected with STIs are asymptomatic18 9
TABLE 1. Demographics and STI Testing Among HIV-Positive Publically Insured Californians, 2010
Overall Syphilis Test Chlamydia Test Gonorrhea Test
N (% of total) n (% of group) P n (% of group) P n (% of group) P
Medicare
Total 11465 7451 (65.0) 3413 (29.8) 3355 (29.3)
Enrollment
Medicare only 3824 (33.4) 2245 (58.7) <0.01 861 (22.5) <0.01 846 (22.1) <0.01
Dual 7641 (66.6) 5206 (68.1) 2552 (33.4) 2509 (32.8)
Sex
Male 10238 (89.3) 6827 (66.7) <0.01 3029 (29.6) 0.22 2987 (29.2) 0.55
Female 1227 (10.7) 624 (50.9) 384 (31.3) 368 (30.0)
Race
White 6664 (58.1) 4283 (64.3) 0.02 1754 (26.3) <0.01 1724 (25.9) <0.01
African American 2124 (18.5) 1383 (65.1) 695 (32.7) 670 (31.5)
Hispanic 2175 (19.0) 1471 (67.6) 830 (38.2) 828 (38.1)
Other 502 (4.4) 314 (62.5) 134 (26.7) 133 (26.5)
Age category, y
<40 835 (7.3) 582 (69.7) <0.01 336 (40.2) <0.01 328 (39.3) <0.01
40–54 6200 (54.1) 4325 (69.8) 2056 (33.2) 2022 (32.6)
≥55 4430 (38.6) 2544 (57.4) 1021 (23.0) 1005 (22.7)
Eligibility
Other 1359 (11.9) 687 (50.6) <0.01 222 (16.3) <0.01 219 (16.1) <0.01
Disabled 10106 (88.1) 6764 (66.9) 3191 (31.6) 3136 (31.0)
Highest-volume HIV provider
0–49 4549 (39.7) 2254 (49.5) <0.01 919 (20.2) <0.01 913 (20.1) <0.01
50+ 6916 (60.3) 5197 (75.1) 2494 (36.1) 2442 (35.3)
Medicaid
Total 3142 2314 (73.6) 1446 (46.0) 1419 (45.2)
Sex
Male 2298 (73.1) 1741 (75.8) <0.01 1035 (45.0) 0.07 1029 (44.8) 0.48
Female 844 (26.9) 573 (67.9) 411 (48.7) 390 (46.2)
Race
White 1151 (36.6) 853 (74.1) 0.40 501 (43.5) <0.01 498 (43.3) <0.01
African American 1051 (33.5) 770 (73.3) 489 (46.5) 470 (44.7)
Hispanic 592 (18.8) 446 (75.3) 310 (52.4) 309 (52.2)
Other 348 (11.1) 245 (70.4) 146 (42.0) 142 (40.8)
Age category, y
<40 570 (18.1) 418 (73.3) 0.02 307 (53.9) <0.01 296 (51.9) <0.01
40–54 1851 (58.9) 1392 (75.2) 848 (45.8) 838 (45.3)
≥55 721 (22.9) 504 (69.9) 291 (40.4) 285 (39.5)
Eligibility
Other 116 (3.7) 73 (62.9) 0.01 51 (44.0) 0.65 51 (44.0) 0.79
Disabled 3026 (96.3) 2241 (74.1) 1395 (46.1) 1368 (45.2)
Highest-volume HIV provider
0–49 1065 (33.9) 682 (64.0) <0.01 484 (45.4) 0.64 479 (45.0) 0.88
50+ 2077 (66.1) 1632 (78.6) 962 (46.3) 940 (45.3)
Landovitz et al.and undiagnosed, the CDC recommends at least annual STI testing
of sexually active PLWH.11 Nonetheless, we found that in 2010,
fewer than two-thirds of HIV-positive Medicare and fewer than
three-quarters of Medicaid enrollees received a test for syphilis.
Rates were even lower for chlamydia and gonorrhea (~30% of
Medicare enrollees and fewer than half of Medicaid enrollees).
Women and older PLWH were significantly less likely to be tested
for bacterial STIs. These findings have implications for both HIV
providers and for health policy.Implications for HIV Providers
Making STI screening (rather than symptom-driven STI
testing) a routine part of medical care for PLWH is important
because it would identify many STIs that are asymptomatic
and that carry significant morbidity and, in rare cases, mortality,
if left untreated. Not only can these STIs be secondarily transmit-
ted, but they also increase HIV infectiousness. Providers often fail
to identify patients who are at risk for STIs because they do not10 Sexuallelicit information on sexual risk behaviors and patients frequently
do not reveal sexual behaviors that would put them at risk for
STIs.21 In particular, gonorrhea and chlamydia are often asymp-
tomatic, so patients are less likely to report symptoms of the infec-
tion that would lead to testing. One study found that symptom- and
sexual history–based testing identified only half of the chlamydia
and gonorrhea cases identified through universal screening.21
Our analyses confirm that testing rates for chlamydia and
gonorrhea infection are low, despite the increase in these infections
in PLWH and their close association with HIV transmission.7–10
Gonorrhea and chlamydia had greater incidence compared with
syphilis among HIV-negative MSM; however, among HIV-positive
MSM, new syphilis were more frequently diagnosed (14.3%) than
chlamydia (8.7%) or gonorrhea cases (10.4%).3 Even PLWH known
to be at risk for STIs are not commonly tested. One study found
that only one-quarter of patients diagnosed as having incident
syphilis were screened for gonorrhea and chlamydia.22
“Opt-out” strategies have been effective in increasing HIV
testing rates and could potentially also increase STI testing. Bloody Transmitted Diseases • Volume 45, Number 1, January 2018
TABLE 2. Logistic Regressions of Testing for STIs Among HIV Positive Publically Insured Californians, 2010
Syphilis Chlamydia Gonorrhea
OR (95% CI) OR (95% CI) OR (95% CI)
Medicare
Dual 1.21 (1.10–1.32) 1.27 (1.15–1.40) 1.28 (1.16–1.41)
Female 0.52 (0.46–0.59) 1.08 (0.94–1.23) 1.03 (0.90–1.18)
African American 1.04 (0.93–1.17) 1.22 (1.09–1.36) 1.19 (1.06–1.33)
Hispanic 1.15 (1.03–1.28) 1.63 (1.47–1.82) 1.67 (1.50–1.85)
Other 1.00 (0.82–1.22) 1.03 (0.83–1.27) 1.04 (0.84–1.29)
Age 40–54 y 0.99 (0.84–1.17) 0.79 (0.68–0.92) 0.80 (0.68–0.93)
Age >55 y 0.68 (0.57–0.80) 0.58 (0.49–0.68) 0.59 (0.50–0.69)
Disabled 1.16 (1.01–1.33) 1.43 (1.21–1.70) 1.43 (1.21–1.70)
Highest-volume provider has 50+ HIV patients 2.92 (2.69–3.16) 2.12 (1.94–2.32) 2.07 (1.89–2.26)
Medicaid
Female 0.66 (0.55–0.79) 1.17 (0.99–1.37) 1.07 (0.91–1.26)
African American 1.03 (0.84–1.25) 1.10 (0.93–1.31) 1.05 (0.88–1.25)
Hispanic 1.18 (0.93–1.49) 1.39 (1.14–1.71) 1.40 (1.15–1.72)
Other 0.85 (0.65–1.12) 0.91 (0.71–1.16) 0.88 (0.69–1.13)
Age 40–54 y 1.03 (0.82–1.29) 0.72 (0.59–0.87) 0.76 (0.63–0.93)
Age >55 y 0.80 (0.62–1.03) 0.57 (0.46–0.72) 0.61 (0.48–0.76)
Disabled 1.33 (0.88–2.00) 1.40 (0.95–2.07) 1.29 (0.88–1.91)
Highest-volume provider has 50+ HIV patients 2.10 (1.78–2.48) 1.04 (0.90–1.21) 1.03 (0.88–1.19)
HIV-Positive Medicare and Medicaid Enrolleesdrawn for monitoring viral loads could be used to screen for syph-
ilis at minimal additional cost and burden. This strategy could
quickly increase the rate of syphilis testing because more than
90% of publicly insured patients living with HIV have been pre-
scribed antiretroviral medications and 85% are regularly tested
for CD4 and/or viral load.23 Increasing screening for gonorrhea
and chlamydia will be more challenging because of the character-
istics of the different tests. Syphilis tests are serologic, but accurate
diagnoses of gonorrhea and chlamydia require rectal, urethral,
and/or pharyngeal samples, which patients find more physically
and emotionally undesirable.24 Indeed, urine testing is the most
common testing modality, but it cannot detect rectal infections.
A study of STI testing ofMSM visiting sexually transmitted disease
clinics found that 83.9% of the MSM were tested for urogenital
gonorrhea and 81.4% for urogenital chlamydia, many fewer than
received rectal tests for gonorrhea (50.4%) or chlamydia (45.9%).
The authors found that 70% of extragenital gonorrhea infection
and 85% of chlamydia infections occurred in MSM who had nega-
tive urethral test results at the same visit. Thus, these infections
would not have been detected by urethral screening alone.25 Studies
of STI testing among MSM have found that only 10% of first
testing episodes included extragenital sites.26 Patient stigma,
shame, fear of invasive sampling, and confidentiality concerns
as well as clinicians' time pressures and lack of cultural compe-
tency act as barriers to testing in rectal sites. Self-collection of
specimens, a method with “acceptable diagnostic accuracy,” is
an alternative that would address both patient and provider
issues.24 Self-collection of rectal swabs has been found as
valid as clinician-collected samples and is equally or more
acceptable to most patients.27
The greater frequency of STI testing among patients with
access to more experienced HIV providers suggests that non-HIV
specialists' lack of prioritization of STI testing or their discomfort
in having anatomically specific discussions of sexual acts and
collecting rectal samples could be barriers to their implementing
routine screening. Indeed, an experiment that both educated
providers about the importance of screening for gonorrhea,
chlamydia, and syphilis and introduced a sexual risk assessment
for patients resulted in significant increases in screening.28 Auto-
mated structural changes, such as including a prompt in the elec-
tronic medical record to screen HIV-positive patients for STIs atSexually Transmitted Diseases • Volume 45, Number 1, January 20regular intervals, could help to overcome a multiple barriers to
routinization of the CDC's STI screening recommendations.Implications for Health Policy
Several policies raise financial hurdles to obtaining preven-
tive screenings for chlamydia and gonorrhea. The US Preventive
Services Task Force finds insufficient evidence of net benefits of
chlamydia and gonorrhea screening in men.29 These screenings
can be financially penalized because insurance reimbursement is
often based on US Preventive Services Task Force evaluations.
Medicarewill cover annual syphilis screening for “men and
women at increased risk for STIs,” but chlamydia and gonorrhea
screening seems to be covered only for pregnant women and
women at increased risk for STIs.30 The high STI incidence rates
among nonpregnant PLWHmeans that many infectionswill go unde-
tected because of lack of symptoms and lack of full sexual histories.
The CDC recommends that laboratories test for gonorrhea
and chlamydia using nucleic acid amplification tests (NAATs),
which have greater sensitivity than culture, but the Food and Drug
Administration (FDA) has not yet cleared NAAT screening for
extragenital specimens.31,32Although laboratories that havemet all
validation requirements for an off-label procedure may use them,
most insurance plans, including Medicare, will not cover non–FDA-
cleared tests. Medicare and Medi-Cal will nominally reimburse
NAAT for diagnostic purposes but will not reimburse for rectal STI
screenings using NAAT technology. Rates of pharyngeal and rectal
infections among asymptomatic HIV-positive MSM are high, so the
lack of FDA clearance of these tests may present a substantial bar-
rier to identifying STIs in extragenital sites. A further hurdle is that
Medicarewill cover only STI screenings ordered by a primary care
provider. More than half of providers to PLWH do not classify
themselves as “primary care” providers; thus, it may be difficult
for them to get reimbursed by CMS for STI screening.32
This study has a number of limitations. First, the data relate
only to California and patients treated in fee-for-service settings
other than federally qualified and rural health centers. Thus, find-
ings may not generalize to other states, managed care settings, or
safety-net providers. Second, the insurance claims data include
only STI tests submitted for insurance reimbursement. However,
we believe that lack of billing is not a major problem because most18 11
Landovitz et al.freestanding STI clinics, such as Planned Parenthood, do bill
Medicare and Medicaid for their publicly insured patients. The
claims data do not indicate whether the sample for gonorrhea
and chlamydia testing was taken from an extragenital site and
perhaps intentionally mislabeled for purposes of testing and/or
billing. However, other studies suggest that extragenital testing
is rare.15 The CDC guidelines apply to sexually active patients.
Although we did not have data on sexual activity, more than
60% of PLWH are sexually active.13 Last, we were unable to as-
sess treatment of STIs, relapses, and reinfections, important pa-
rameters in completing the understanding of the STI diagnostic
and therapeutic landscape.
Our study also has a number of strengths. It uses STI testing
data for bacterial STIs for large numbers of Medicare and
Medicaid enrollees with HIV, a group with very high rates of STIs.
It examines care for PLWH in a wide variety of settings and
is not limited to a small sample or a single clinic, as in many
prior analyses.
Increasing rates of condomless anal sex among MSM have
led to increases in STIs at the same time that transmission of HIV
has fallen as a result of antiretroviral therapy's effect on reducing
HIV viral loads.1,2 Untreated STIs adversely affect the health of
patients with HIV and increase the likelihood of transmitting the
HIV virus to others. Incorporating STI testing as a routine part
of HIV care and treatment visits would increase detection and
treatment of STIs for PLWH. However, the lack of FDA approval
for NAATon rectal and pharyngeal samples remains a significant
barrier. Regular STI screening constitutes an important component
of medical care for people with HIV infection such that the infec-
tions can be treated to reduce morbidity and secondary transmission
of the both HIVand STIs to others.REFERENCES
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